Vanda Pharmaceuticals is developing tradipitant, a novel, oral treatment for the symptoms of gastroparesis. Tradipitant is a dual 5-HT3 and NK1 receptor antagonist in development for the treatment of gastroparesis. Vanda plans to initiate a Phase 2 clinical trial of tradipitant in gastroparesis patients. In the Phase II study, patients were randomized to receive tradipitant or placebo and followed for a period of 28 days.
During this time, they could be treated with rescue medication if their OAB symptoms became bothersome. In the treatment arm receiving tradipitant, patients had significantly lower use of rescue medication compared to those in the placebo arm (2.6 vs. 3.8 doses per patient).
The majority of these doses were prescribed at a fixed time interval after drug administration Tradipitant is a first-in-class, orally available NK1 receptor antagonist for the treatment of patients with pain due to osteoarthritis and postoperative pain. Tradipitant has been studied in two Phase 3 clinical trials, TAP201 and TAP202, both of which were designed to evaluate the efficacy and safety of tradipitant as compared to placebo in patients with osteoarthritis knee pain.